Yahoo Web Search

Search results

    • Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

      WKRN Nashville· 13 hours ago

      ...registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax- New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in...